What's Hot
View all perspectives
Robert B Chao, MD doctorRBC
2 years 5 months ago
Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-controlled study
Met primary endpoint SRI response across all doses
No death, MACE, VTE, systemic infections
@RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Robert B Chao, MD doctorRBC
2 years 5 months ago
Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%)
Less flare occurrences
Sarilumab noted to have higher incidences of neutropenia, arthralgia
@RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
Dr. Antoni Chan synovialjoints
2 years 5 months ago
Witholding MTX after both doses or only after the second dose of ChAdOx1 vaccine yields higher antibody repsonse compared to continuing MTX. Witholding MTX after second dose reduced the risk for flare. Data from MIVAC 1 and 2 #EULAR2022 @RheumNow LB https://t.co/GfL4eDXchb
Dr. Antoni Chan synovialjoints
2 years 5 months ago
In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
TheDaoIndex KDAO2011
2 years 5 months ago
Great visual on how #socialmedia can further research and medical education #eular2022 @rheumnow @UnaMakris
@UTSWRheum https://t.co/3OiQ6CggnA
Dr. John Cush RheumNow
2 years 5 months ago
#EULAR2022 â Day 3 Report
We are sharing our favorite presentations from Day 3.
https://t.co/Kntt7qiHA5 https://t.co/Z3t5m81TDj
Robert B Chao, MD doctorRBC
2 years 5 months ago
New biomarker for atherosclerosis, cardiovascular risk and disease activity in axSpA?
Low Irisin associated with subclinical atherosclerosis, high CV risk and more severe disease activity in axSpA
@RheumNow #EULAR2022 ABST#POS0327
Richard Conway RichardPAConway
2 years 5 months ago
Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) @RheumNow #EULAR2022 POS0774 https://t.co/a5dToAuao9
Janet Pope Janetbirdope
2 years 5 months ago
Sing an ARIAA! #Bestinclass Rx of arthralgia w +MRI showed delay of #rheumatoid arthritis w #Abatacept vs #placebo. NNT to prevent 1 RA [is 8 w Rx for 1 yr & then d/c-Yrs ago #MTX delayed onset of RA but benefit waned after d/c Rx. Both ?RA spectrum POS0531 @RheumNow #EULAR2022
Robert B Chao, MD doctorRBC
2 years 5 months ago
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo
Efficacy as early as 2 weeks
No MACE, uveitis, IBD, deaths
@RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi
David Liew drdavidliew
2 years 5 months ago
72% of you would treat some high-risk subclinical arthralgias with MTX
and Marta Mosca, in the #EULAR2022 highlights, broadly agrees
OP0070 Leiden data showed better function and presenteeism. And thatâs a win in my book
@RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71
David Liew drdavidliew
2 years 5 months ago
Biosimilars and COVID vaccines have made nocebo more pertinent than ever.
How do we combat it?
First line is good communication, and the foot soldiers are the right phrases.
Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#OP0004 #EULAR2022 In line with EULAR Presidentâs preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network @RheumNow https://t.co/h03mieTcQt
David Liew drdavidliew
2 years 5 months ago
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.
In the 2022 version:
JAKi now separate sentence following bDMARDs, with proviso to mention risk.
Sometimes guidelines have to tell us what weâve all inevitably been expecting
#EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 POS0285
130K UK patients had incident gout bw 2004-2020
âď¸Only 29% started on ULT w/in 12 mos
âď¸Target urate level only 14% in 2004, only to 17% in 2020
Updated EULAR guidelines in 2016: No statistical difference in ULT Rx or target attainment
@Rheumnow
Poster Hall